Eisai Co., Ltd. and Biogen Inc. announced that the European Medicines Agency had accepted a marketing authorization application for lecanemab, an investigational anti-amyloid beta protofibril antibody, for the treatment of early Alzheimer’s disease with confirmed amyloid pathology, for review following a standard timeline.
[Biogen, Inc.]
